SUCCESSFUL PHASE II STUDY EXPANDS THE POTENTIAL FOR EPROTIROME IN DYSLIPIDEMIA TREATMENT
Karo Bio has successfully completed a 10 week phase IIb study with eprotirome given to dyslipidemia patients undergoing treatment with the cholesterol absorption inhibitor ezetimibe. Eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein(a) and was safe and well tolerated. Data show that eprotirome in combination with ezetimibe can become an important treatment option for patients with dyslipidemia.Karo Bio’s compound eprotirome is a novel, liver selective, thyroid hormone receptor agonist with a promising